Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Leuven, BELGIUM, Boston, MA, US – November 3, 2023 – 08.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 77,639,751 new ordinary shares on November 2, 2023, for a total amount of EUR 50,000, as the result of the conversion of 2 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,956,764,011 outstanding ordinary shares carrying voting rights (compared to 2,879,124,260 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
| 83,006,161.32 |
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Chief Executive Officer
Tel: +32 16 75 13 10
Chief Business Officer
Tel: +32 16 75 13 10
Mary T. Conway
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Buy-backs of shares in CoinShares International Limited29.11.2023 09:00:00 CET | Press release
29 November 2023 | SAINT HELIER, Jersey - As announced on 07 November 2023, the Board of Directors of CoinShares International Limited ("CoinShares" or the "Company") (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF), Europe's leading alternative asset manager specialising in digital assets, resolved to extend a share buy-back program and repurchase shares on Nasdaq Stockholm Market during the period 07 November 2023, up to and including 30 May 2024 for total maximum amount of SEK 30 million in accordance with the authorisation from the Annual General Meeting on 31 May 2023. The Board of Directors’ resolution to implement the share buy-back program was made after the Board's review of the Company's capital structure and was implemented for the purposes of reducing the capital of the Company. The share buy-back program is carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulatio
Deutsche Digital Assets Wins Pension Fund as Anchor Investor for DDA Crypto Select 10 ETP (SLCT)29.11.2023 09:00:00 CET | Press release
Institutional anchor investor for DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0; WKN: A3G3ZD, Ticker: SLCT) The DDA Crypto Select 10 ETP reflects the MarketVector™ Digital Assets Max 10 VWAP Close Index (“MVDAMV”)With the ETP, investors are in a position to affordably gain exposure to a basket collection of (up to) the 10 most important crypto assetsThe ETP is 100% collateralized by coins held in an institutional custody solution FRANKFURT, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Deutsche Digital Assets GmbH has gained a renowned institutional anchor investor for the DDA Crypto Select 10 ETP (ISIN: DE000A3G3ZD0 | WKN: A3G3ZD), which was launched in June 2023. DDA prevailed against the competition in a selection process and was commissioned to design a crypto ETP that meets high quality standards and strict requirements of an institutional investor. After several months of preparation, this investment product can now be administered by a leading capital management company acting on be
Yara helps farmers combat the effects of climate change and improve nutrient use efficiency29.11.2023 08:40:00 CET | Press release
Global rise in temperatures has introduced a challenging reality for farmers worldwide. To meet the increasing demand for solutions to protect crops against climate change and optimize nutrient use efficiency, Yara is launching YaraAmplix™. A new brand that will expand the range of biostimulants. November 29th 2023 Milan: Climate change is putting many of the world’s most popular foods such as maize, tomato and wheat at risk of reduced crops. With the average global temperature on earth having already increased by over 1 degree Celsius in the last 100 years*1, agriculture is now experiencing more extreme weather than ever before with temperature increases being most severe on land. In response to farmers asking for solutions to increase crop resilience and nutrient use efficiency, Yara today announces the launch of YaraAmplix, a new brand of biostimulants, at the Biostimulant World Congress in Milan, Italy. “Extreme weather is destroying crops all over the world with drought, flooding
Sanoma Corporation - Managers' Transactions29.11.2023 08:30:00 CET | Press release
Sanoma Corporation, Managers’ Transactions, 29 November 2023 at 9:30 EET Sanoma Corporation - Managers' Transactions ___________________________________________ Person subject to the notification requirement Name: Holding Manutas Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Herlin Anna Position: Member of the Board Issuer: Sanoma Oyj LEI: 743700XJC24THUPK0S03 Notification type: INITIAL NOTIFICATION Reference number: 44711/8/10 ____________________________________________ Transaction date: 2023-11-28 Venue: AQEU Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1): Volume: 250 Unit price: 6.87 EUR (2): Volume: 32 Unit price: 6.9 EUR Aggregated transactions (2): Volume: 282 Volume weighted average price: 6.8734 EUR ____________________________________________ Transaction date: 2023-11-28 Venue: BEUP Instrument type: SHARE ISIN: FI0009007694 Nature of transaction:
Delårsrapport for 1. januar - 30. september 2023 for FirstFarms A/S29.11.2023 08:05:40 CET | pressemeddelelse
FirstFarms leverer tilfredstillende i udfordrende marked FirstFarms skaber fornuftige resultater på trods af høj inflation på omkostninger og stort pres på salgspriser. Omsætningsfremgang på 19% og fastholdelse af udmeldte forventninger til året. Bestyrelsen og direktionen i FirstFarms A/S har d.d. behandlet og godkendt det ureviderede delårsregnskab for perioden 1. januar - 30. september 2023. FirstFarms har i regnskabsperioden realiseret: Omsætning: 345 mDKK (2022: 291 mDKK)EBITDA: 79 mDKK (2022: 121 mDKK)EBIT: 42 mDKK (2022: 89 mDKK)Resultat før skat: 28 mDKK (2022: 77 mDKK) Produktion og resultatskabelse er tilfredsstillende med baggrund i de udfordrende forudsætninger FirstFarms har opereret under i årets første tre kvartaler. Resultatet er skabt som følge af en stabil, effektiv, cirkulær drift samt den risikospredning, der er et positivt og væsentligt særkende for koncernen. FirstFarms A/S fastholder derfor de udmeldte forventninger for 2023. Dog med et EBITDA i den nedre del af